Registry Study for Talimogene Laherparepvec
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
- Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
- Eligible Ages
- Between 18 Years and 99 Years
- Eligible Genders
- Accepts Healthy Volunteers
All subjects must provide informed consent prior to initiation of any study activities.
All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment and participation, including long-term follow-up (if applicable) in that trial.
Subjects currently receiving talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial.
Subject currently participating, including for long-term follow-up (if applicable), in other Amgen-sponsored talimogene laherparepvec clinical trial.
- Study Type
- Observational [Patient Registry]
- Observational Model
- Time Perspective
|Previously treated with T-VEC||Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial||
- NCT ID
- Enrolling by invitation
A registry study is to evaluate the overall survival, use of subsequent anti-cancer therapy, and the long-term safety of subjects who have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type. Follow-Up will occur every 3 months.